ACADIA Pharmaceuticals Inc

ACAD

Add to Watchlist

22.400USD

-0.160-0.71%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

ACADIA Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

9 / 384

Overall Ranking

81 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

ACADIA Pharmaceuticals Inc Highlights

StrengthsRisks

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 47.50% year-on-year.

Fairly Valued

The company’s latest PE is 10.05, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 164.70M shares, decreasing 11.36% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 174.00 shares of this stock.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

31.526

Target Price

+39.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of ACADIA Pharmaceuticals Inc is 8.05, ranking 50 out of 384 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 268.06M, representing a year-over-year increase of 9.72%, while its net profit experienced a year-over-year increase of 80.84%.

Score

Industry at a Glance

Previous score

8.05

Change

0



Financials

8.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.50

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.53

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.39

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of ACADIA Pharmaceuticals Inc is 6.50, ranking 255 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is 10.04, which is 928.90% below the recent high of 103.35 and 21622.87% above the recent low of -2161.97.

Score

Industry at a Glance

Previous score

6.50

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/384

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of ACADIA Pharmaceuticals Inc is 7.90, ranking 267 out of 384 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 35.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

7.90

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of ACADIA Pharmaceuticals Inc is 8.43, ranking 88 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 23.33 and the support level at 21.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.62

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of ACADIA Pharmaceuticals Inc is 10.00, ranking 1 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.20%, representing a quarter-over-quarter decrease of 13.39%. The largest institutional shareholder is Steven Cohen, holding a total of 3.38M shares, representing 1.97% of shares outstanding, with 28.97% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

42.90M

--

BlackRock Institutional Trust Company, N.A.

18.44M

+2.76%

State Street Investment Management (US)

7.91M

+9.03%

RTW Investments L.P.

7.14M

--

Point72 Asset Management, L.P.

Star Investors

3.38M

+127.22%

Geode Capital Management, L.L.C.

3.24M

+3.41%

Dimensional Fund Advisors, L.P.

2.92M

+4.39%

Palo Alto Investors LP

2.48M

+0.70%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ACADIA Pharmaceuticals Inc is 7.68, ranking 8 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

ACADIA Pharmaceuticals Inc

ACAD

8.02 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment